Kornimate/medical-research-clean huggingface dataset:
crossover study from macitentan or bosentan over to ambrisentan

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (tracleer) or macientan (opsumit) to ambrisentan (letairis) over 24 weeks in subjects with connective tissue disease associated pulmonary arterial hypertension (ctd-pah).

the study will consist of a group of subjects who have been on bosentan for at least three months and a group that has been on macitentan for at least three months. both groups will be switched to letairis 5mg daily after the bosentan or macitentan therapy for three months and then increased to a dose of letairis 10mg daily at week 4 if well tolerated.

Eligibility criteria:
inclusion criteria: * diagnosis of a connective tissue disease (ctd) * age range: 18-80 years old * previous right heart catheterization (rhc) demonstrating pah * forced vital capacity (fvc) greater than 50% * carbon monoxide diffusing capacity (dlco) greater than 50% * world health organization (who) functional class ii or iii * able to perform a 6 minute walk test (6mwt) * stable dose of antihypertensive medications * non-pregnant females * have to be currently on stable dose of bosentan for at least 3 months * adequate acoustic images to allow for transthoracic echocardiography to be performed exclusion criteria: * exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis) * severe systemic hypertension greater than 170/95 * patients with a prior history of cardiovascular disease * who functional class iv status * patients with severe other organ disease felt by investigators to impact on survival during the course of the study. * fvc less than 50% of predicted * dlco less than 50% of predicted
effect of african drumming in mood disorders

Conditions: Depressive Disorder; Bipolar Disorder

Summary: this pilot study evaluated whether participating in an african drumming activity for 45 minutes immediately improved mental well-being among 13 adults diagnosed with acute mood disorders who were attending a private mental health clinic. the drumming intervention was completed by occupational therapists.

this pilot study evaluated the effectiveness of an occupational therapy-led african drumming group on mental well-being among adult psychiatric inpatients with mood disorders. a secondary purpose was to test a protocol for the delivery of african drumming interventions to adults with acute mood disorders. a quasi-experimental uncontrolled one-group pre-test-post-test design was used to collect data during six drumming groups at an acute mental health clinic. thirteen adults completed assessments of different aspects of mental well-being, including mood and enjoyment, before and after the intervention. because this was a pilot study, participants were not assigned to any comparison groups. in addition, in-patients at the clinic received the intervention whether they participated in the study or not. improvement in mental well-being across different domains of mental well-being was expected, including feelings of anger, tension, confusion, depression, fatigue and vigour. the researchers also expected the intervention to be more effective in participants with previous drumming experience, and in those with lower levels of anxiety and depression.

Eligibility criteria:
inclusion criteria: * attending mental health clinic * diagnosed mood disorder * voluntarily attending drumming group exclusion criteria: * psychosis
exploratory study of precise therapy for advanced tumor patients with malignant hydrothorax or ascites by using ptc drug sensitivity testing

Conditions: Lung Cancer; Breast Cancer; Gastric Cancer; Colorectal Cancer

Summary: to explore the consistency between result of ptc drug screening tests and actual clinical outcome for patients with advanced malignancy.

this study is anticipated to enroll 55 patients with advanced malignancy, and fresh malignant effusion samples collected from patients would be detected by ptc drug screening. in addition, patients would receive 2 cycles of personal therapy based on results of screening tests. by combining ptc drug sensitivity results with patient's treatment process and clinical feedback, researchers may evaluate the sensitiveness and specificity of ptc drug screening technique in predicting clinical outcome for advanced malignancy patients.

Eligibility criteria:
inclusion criteria: 1. 18 to 75 years old, regardless of gender. 2. score of nutrition risk screening 2002 (nrs2002) is less than 3, nrs20023. 3. advanced and unresectable malignancy confirmed by biopsy diagnosis. 4. able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases. 5. score of eastern cooperative oncology group (ecog) is not higher than 2, ecog≤2. 6. anticipated survival exceed six months. 7. at least one measurable lesions (according to recist 1.1) 8. resistance or intolerance to standard therapy regimens. 9. signed informed consent form voluntarily. exclusion criteria: 1. pregnant or lactating women. 2. have participated other clinical trials in six months. 3. severe liver dysfunction. 4. severe renal dysfunction. 5. patients with cognitive disorder, mental diseases and terrible compliance. 6. allergic to known chemotherapeutic agents. 7. other circumstance not suitable to participate in this trial determined by investigators.

Keywords: ptc: patient-derived tumor-like cell clusters
sensitivity of hyomental distance ratio as a single predictor of difficult intubation in obstetrics

Conditions: Caesarean Section

Summary: this is a study to detect the sensitivity of thyromental distance ratio as a single predictor for difficult intubation in patients undergoing cesarean section under general anesthesia.

the authors intend to use the hmdr for detection of difficult intubation in parturient undergoing cesarean section that is either elective or emergency.

Eligibility criteria:
inclusion criteria: * all patients presenting for cesarean section under general anesthesia exclusion criteria: * none

Keywords: difficult intubation hyomental distance obstetric mallampati classification thyromental distance sternomental distance
l. plantarum 299v and gut microbiome, diarrhoea, and clostridioides difficile infection in colorectal cancer patients

Conditions: Colorectal Cancer; Clostridioides Difficile Infection; Diarrhea

Summary: colorectal cancer in periooperative period patients (n=60) will be enrolled to this study. participants will be divided into 4 groups as follows: * group 1 (n=15) will receive 2 capsules (per day) of l. plantarum 299v l. plantarum 299v (sanprobi ibs®) for 4 weeks * group 2 (n=15) will receive l. plantarum 299v (2 capsules per day) and inulin (4 g) for 4 weeks * group 3 (n=15) will receive placebo (2 capsules per day) and inulin (4 g) for 4 weeks * group 4 (n=15) will receive placebo (2 capsules per day) for 4 weeks


Eligibility criteria:
inclusion criteria: * age ≥18 oraz ≤65 * patients with colorectal cancer prior to surgical treatment * qualification to surgery * the treatment with chemotherapy and radiotherapy in preoperative period * an appropriate swallowing * patients agreement to take part in this study exclusion criteria: * the presence of other cancers than colorectal cancer * inflammatory bowel diseases * dysphagia * intake of antibiotics, proton pump inhibitors, probiotics, and synbiotics 3 months befor taking part in this study

Keywords: lactobacillus plantarum 299v probiotics colorectal cancer clostridioides difficile diarrhea
clinical evaluation of zirconia crowns and anterior strip crowns

Conditions: Dental Caries

Summary: the hypothesis to be investigated is that no difference will be found upon comparing resin composite strip crowns and nusmile zirconia crowns (nusmile zr) esthetic primary anterior in restoring anterior primary teeth.

the aim of this study is to clinically evaluate the performance of a new nusmile zr esthetic primary anterior crowns, compared with anterior resin composite strip crowns in the restoration of 120 teeth (primary incisors and lateral anterior teeth in the deciduous dentition of child patients).

Eligibility criteria:
inclusion criteria: * healthy children with no history of any systemic illness or any developmental disease of the teeth and jaws that would have affected dietary patterns, caries, susceptibility or the selection of restorative materials to the best of current knowledge. * minimal of two surfaces of caries in the targeted tooth. * patient with early childhood caries as defined by american academy of pediatric dentistry (aapd), 2016. * cooperative patient who had behavioral rating "positive" or "definitely positive" followed the frankl behavior classification scale. (frankl et al. 1962) * opposing teeth present. * written consent was obtained from the parent/guardian after explaining the full details of the treatment procedure and its possible outcomes, discomfort, risks, and benefits. * no patient was excluded on the basis of gender, race, social or economic background. exclusion criteria: * teeth with proximity to exfoliation and resorption of the root passed its half. * patients with allergy or hypersensitivity to nickel in case of posterior group teeth. * presence of single surface caries not involving the proximal surfaces. * teeth that has been subjected to trauma. * anxious, uncooperative patients who need to be treated under general anesthesia. * children who suffer from bruxism. * children with special needs. * presence of tooth wear on the opposing teeth (in case of anterior teeth), or absence of opposing.

Keywords: caries full coverage strip crown zirconia crown primary anterior teeth crown
vericiguat drug-drug interaction study with isosorbite mononitrate in stable coronary artery disease patients

Conditions: Coronary Artery Disease

Summary: this study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.


Eligibility criteria:
inclusion criteria: patients with stable cad defined by * coronary artery stenosis in any of the 3 main coronary vessels \> 50% documented by coronary angiography within last 36 months * or history of myocardial infarction * age: 30 to 80 years (inclusive) at the first screening examination * body mass index (bmi): above/equal 18.0 and below/equal 36.0 kg / m² exclusion criteria: * intervention e.g. revascularization by percutaneous coronary intervention (pci) and/or coronary artery bypass graft (cabg) during the last 3 months * progressive angina with symptoms of worsening of angina within the \< 3 months prior to the first screening examination * history of recent (\< 6 months prior to the first screening examination) myocardial infarction or unstable angina * symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement * insulin dependent diabetes mellitus * clinically relevant cardiac ischemia at screening * clinical significant persistent ischemia, which should be ruled out by clinical judgment of the investigator, based on medical history, available clinical data e.g. past angiograms or preexisting or current exercise testing with any imaging technique (e.g. dobutamine stress echocardiography, adenosine or dobutamine stress cardiac magnetic resonance imaging (cmr), scinthigraphy or exercise ecg) * atrial fibrillation, pacemaker, defibrillator, atrial ventricular (av)-block ii and iii * systolic blood pressure below 110 or above 160 mmhg at first screening visit * diastolic blood pressure above 100 mmhg at first screening visit * heart rate below 50 or above 100 beats / min (taken from ecg measurement) at first screening visit * estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73m\*2 at first screening visit
dietary antioxidants and atherosclerosis

Conditions: Atherosclerosis; Cardiovascular Diseases; Heart Diseases; Carotid Stenosis

Summary: to examine the role of dietary antioxidants in the etiology of atherosclerosis in both sexes and in whites and blacks.

background: atherosclerosis is this nation's leading cause of death for males and females, and blacks and whites. there is mounting evidence that the oxidation of blood low density lipoproteins (ldl) plays an important role in the pathogenesis of this disease. ldl oxidation can be prevented by several dietary antioxidants, in particular, vitamin c, vitamin e, and beta-carotene. there is preliminary evidence that dietary antioxidants may slow the natural history of atherosclerosis in humans. until now studies in this area have included predominantly white males with symptomatic disease. design narrative: the case-control study used data collected in aric to test the hypothesis that individuals in the lowest quintile of vitamin c, vitamin e and carotenoid consumption were at higher risk of asymptomatic atherosclerosis than those consuming greater amounts. antioxidant intake was assessed by a validated food frequency questionnaire and a diet supplement survey. cases were those with asymptomatic carotid artery atherosclerosis as determined by b-mode ultrasonography. controls were those without evidence of carotid artery atherosclerosis. secondary analyses determined which sex-race subgroups were at particular risk due to low antioxidant consumption. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
hpv genotyping by dr. hpv genotyping in vitro diagnostic device (ivd) kit in exfoliated cells of the uterine cervix

Conditions: Cervical Intraepithelial Neoplasia; Human Papillomavirus Infection; HPV Infection

Summary: high-risk type human papillomavirus (hpv) is the known etiological agent of cervical cancer. hpv testing and risk stratification by genotyping has been recognized as an effective cervical screening program. a chip for hpv dna typing based on type-specific polymerase chain reaction (pcr), dr. hpv genotyping ivd kit (hpv-27) was developed for genotyping of 27 common hpv types including all high-risk types. we studied its agreement, sensitivity, and specificity compared to dna sequencing as the gold standard.

high-risk type human papillomavirus (hpv) is the known etiological agent of cervical cancer. hpv testing and risk stratification by genotyping has been recognized as an effective cervical screening program. hpv detection is also applied for triage of atypical squamous cells of undetermined significance and follow-up after treatment for cervical neoplasms. a chip for hpv dna typing based on type-specific polymerase chain reaction (pcr), dr. hpv genotyping ivd kit (hpv-27) was developed for genotyping of 27 common hpv types including all high-risk types. we studied its agreement, sensitivity, and specificity compared to dna sequencing as the gold standard. one-thousand one-hundred and three (1103) subjects were enrolled between december 2012 and december 2013 from linkou chang gung memorial hospital, mackay memorial hospital, changhua christian hospital, and cathay general hospital.

Eligibility criteria:
inclusion criteria: 1. 21-65 y/o female with sexual exposure 2. written informed consent 3. either one of the following conditions: 3a. no previous history of abnormal cervical cytology or abnormal histology for women enrolled in no intraepithelial lesion or malignancy (nilm) group 3b. abnormal cervical cytology other than atrophic change, reactive change or glandular cells favored of the endometrial origin exclusion criteria: 1. current pregnancy 2. previous total hysterectomy 3. cervicovaginal infection required treatment 4. received cervical ablative therapy within 1 year
palatability of oral rehydration solutions

Conditions: Gastroenteritis

Summary: the primary objective of this study is to compare the mean taste scores for three fruit flavored oral rehydration solutions in children aged 5-10 years old. the secondary objective is to compare the proportions of children who indicate a taste preference for one of the solutions.

in canada, acute gastroenteritis remains a major cause of morbidity and hospitalizations. this, in large part, is due to an inability to realize the full benefits of oral rehydration therapy. because oral rehydration solutions have a salty taste, many mild to moderate dehydrated children refuse to drink them. this has resulted in pediatricians recommending inappropriate solutions and the unnecessary administration of intravenous fluids. although two meta-analyses have concluded that rice-based ors (enfalyte) is as or more effective than traditional ors in reducing stool output, the palatability of different oral rehydration solutions have never been evaluated. this will be the first prospective trial comparing the palatability of the most commonly recommended oral rehydration solutions, pedialyte and enfalyte with a newer solution, pediatric electrolyte. both pedialyte and pediatric electrolyte contain sucralose, dextrose, and fructose while enfalyte contains rice syrup solids. although the latter is as, or more effective than pedialyte in reducing stool output, palatability may limit its use. taste is important as children with gastroenteritis are frequently nauseated and may refuse to drink or vomit when consuming less palatable solutions. we hypothesize that, compared to children who receive a rice-based ors (enfalyte), those who receive a sucralose ors (pediatric electrolyte or pedialyte) will report a higher mean taste score, will prefer to drink the sucralose sweetened ors if they had to consume a larger volume, and are more likely to drink the entire volume they are provided.

Eligibility criteria:
inclusion criteria: * children 5-10 years of age evaluated in the hospital for sick children's emergency department exclusion criteria: * children with diarrhea, a vomiting or diarrhea episode within 24 hours, head trauma, abdominal pain, upper respiratory symptoms, or nil per os status * patients with gastrointestinal symptoms

Keywords: gastroenteritis pediatrics rehydration therapy
antidepressive effect on 5 herz (hz) rtms over dorsomedial prefrontal cortex and left dorsolateral prefrontal cortex

Conditions: Major Depressive Disorder

Summary: this study evaluates the efficacy of 5hz repetitive transcranial magnetic stimulation (rtms) over left dorsolateral prefrontal cortex and dorsomedial prefrontal cortex on major depressive disorder (mdd).

major depressive disorder (mdd) affects a significant percentage of the national population (17-20%) in 2:1 ratio in women compared to men. repetitive transcranial magnetic stimulation (rtms) is an effective neuromodulation technique for the treatment of major depressive disorder and it has demonstrated favorable clinical effects when applied over the left dorsolateral prefrontal cortex (ldlpfc); however there is evidence that other areas of the prefrontal cortex such as the dorsomedial prefrontal cortex (dmpfc) could be ideal for rtms treatment targets during the presence of mdd, given its association with deficient cognitive processes during the course of the illness. there is also evidence of the use of 5hz frequency with the same clinical effectiveness from other frequencies such as 10 hz and 20 hz when applied to the ldlpfc. however, there are no current research that have addressed the use of this frequency on dmpfc.

Eligibility criteria:
inclusion criteria: * 18-45 years old. * meet dsm 5 (diagnostic and statistical manual, 5 edition) diagnostic criteria for major depressive disorder. * score \>17 in hamilton depression rating scale. exclusion criteria: * subjects with diagnose of psychotic depression, schizophrenia, bipolar disorder, post traumatic stress disorder. * subjects with epilepsy or presence of paroxysms during the eeg. * subjects with previous history of traumatic brain injury, metal plates in the skull, cochlear devices, infusion devices such as insulin pumps.

Keywords: depression major depressive disorder
utilizing activity trackers to promote physical activity in people with epilepsy: can we make a difference?

Conditions: Epilepsy

Summary: the purpose of this study is to evaluate standard of care exercise education alone or in combination with a wearable physical activity tracker in people with epilepsy (pwe) to determine the most effective way to increase physical activity and measure impact on depression, anxiety, quality of life, sleep, and seizure frequency.


Eligibility criteria:
inclusion criteria: * patient of the texas comprehensive epilepsy program at uthealth-mcgovern medical school * diagnosis of epilepsy * be able to provide consent in english * complete surveys independently * be able to sync fitbit data exclusion criteria: * currently using a wearable physical activity tracker prior to enrollment * pregnant or planning to become pregnant during the study duration * planning to undergo epilepsy surgery during the study duration

Keywords: epilepsy exercise activity tracker
effect of testosterone therapy in men with alzheimer's disease and low testosterone

Conditions: Alzheimer's Disease; Hypogonadism

Summary: treatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and alzheimer's disease. improved performance on these tests may mean an improved ability to get around in one's environment without getting lost or injured. this could have a positive impact on both patients and those who care for them. we will investigate what areas of the brain are involved in these improvements in spatial ability. this will be done using a pet scan, which creates a 3-dimensional image of the brain that can allow us to see how the brain functions.

volunteers will be treated with a prescription testosterone gel applied to the shoulder or other body area each day. this treatment will continue for 6 months. subjects will undergo a pet scan at the beginning of the study and after approximately 2 months of treatment. subjects will undergo some cognitive testing throughout the study.

Eligibility criteria:
inclusion criteria: * alzheimer's disease diagnosis, based on diagnostic and statistical manual of mental disorders (5th ed.; dsm-v) * total testosterone \< 300 ng/dl and/or calculated free testosterone \< 50 pg/ml * sufficient english to perform cognitive testing * stable on concomitant medications for 1 month prior to starting study exclusion criteria: * history of prostate cancer * history of breast cancer * gonadal endocrine disorders * current major psychiatric illness (excluding depression) * significant uncontrolled systemic illness * recent myocardial infarction (within 6 months) * renal or hepatic disease, sleep apnea * history of alcoholism or substance abuse within the past year * history of head injury with loss of consciousness greater than 1 hour * testosterone or other androgen treatment within past 3 months * history of taking other drugs that might interfere with the results of the study (ie, spironolactone, cimetidine, antiandrogens, estrogens, p450 enzyme inducers, barbiturates) * symptomatic bph: prostatic symptoms, prostatic masses or induration on rectal examination * prostate specific antigen (psa) \>4.0 mg/ml * hemoglobin \> 17 mg/dl * generalized skin disease that could affect the absorption of testosterone gel (ie, psoriasis). * potentially agitated or uncooperative for procedures

Keywords: testosterone hypogonadal cerebral glucose metabolism pet scan alzheimer's disease